Lysosomal Phospholipase A2 (LPLA2) Activity as a Diagnostic and Therapeutic Target for Identifying and Treating Systemic Lupus Erythematosus

摘要

The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.

主权项

1. A method of reducing accumulation of intracellular tingible body macrophages comprising the step of contacting a cell having an accumulation of tingible body macrophages with an agent having lysosomal phospholipase A2 (LPLA2) enzymatic activity in an amount effective to reduce the accumulation of tingible body macrophages.